Tirzepatide (GIP + GLP-1 agonist)
Tirzepatide (Brand name “Mounjaro”) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated for improving glycemic control in adults with type 2 diabetes. One of the mechanisms tirzepatide uses to accomplish this is it delays gastric emptying, which causes a decrease in appetite, which is why it is also prescribed off-label for helping with weight loss.
Tirzepatide mimics a hormone that regulates appetite and food intake in the brain. This can help you feel full and eat less, which can lead to weight loss. Tirzepatide is not insulin. You can take it with or without food. Like semaglutide (brand name “Wegovy/Ozempic”), tirzepatide (“Mounjaro”) is a GLP-1 agonist. GLP-1 agonists send signals to your brain to regulate metabolic function, help you feel full, and decrease your appetite. People who hold onto more weight have reduced GLP-1 signaling, according to research. Wegovy (semaglutide) and Ozempic (semaglutide) activate the GLP-1 pathway, while Zepbound (tirzepatide) and Mounjaro (tirzepatide) activate two: both GLP-1 and GIP which tends to lead to more weight-loss in many patients.
The most common side effects reported by patients taking tirzepatide are nausea, diarrhea, decreased appetite, indigestion, vomiting, constipation, and stomach pain. Side effects may vary and should be evaluated by the health care provider for appropriate management.
Patients may find it helpful to:
While GLP-1s like semaglutide and tirzepatide are powerful, our program and your weight loss are about much more than the medication alone. Patients will be expected to exercise regularly and eat a healthy diet.
Before being prescribed tirzepatide for weight loss, an initial weight loss consultation will be required where a medical history, medical exam, and lab work will be completed to determine whether tirzepatide is an appropriate option for the patient.
Tirzepatide is administered via subcutaneous injection once per week, ideally on the same day each week. (Ie. Pick a “shot day” – Many patients choose Friday so that if they experience any of the side effects, they have the weekend to manage these symptoms.) If a weekly dose of tirzepatide is missed, administer the dose as soon as possible within 4 days after the missed dose. If a dose is missed by more than 4 days, skip it and continue with the regular dosing schedule.
Initial dosing of tirzepatide will always start at 2.5 mg weekly. The medical provider may increase the dose after the first month (4 weeks of receiving consecutive 2.5 mg injections weekly) to 5 mg weekly depending on tolerance to the medication, side effects reported, weight loss progress, etc. Dosing is up to the sole discretion of the medical provider. Your health and safety are our ultimate concern and dosing will be done accordingly. Do not adjust your medication dose without consulting with the medical provider. Do not skip doses. If you miss 2 weeks or more of tirzepatide doses, you will be required to have another medical visit with the provider to discuss options for continuing on tirzepatide and your dosage may have to be adjusted down. In order to prevent this from happening, do not miss scheduled follow up visits and keep your medication secure and refrigerated at all times. Do not allow anyone else to take your medication.
Men experience age-related hormonal changes in a process that many physicians refer to as andropause, which is caused by a decrease in testosterone.
Andropause is caused by a decrease in testosterone. We can administer testosterone therapy to increase testosterone in the body.
We recommend testosterone treatments every 2-4 weeks, depending on our thorough clinical assessment.
We Are Here to Help